» Articles » PMID: 17456052

The CXCR4 Chemokine Receptor in Acute and Chronic Leukaemia: a Marrow Homing Receptor and Potential Therapeutic Target

Overview
Journal Br J Haematol
Specialty Hematology
Date 2007 Apr 26
PMID 17456052
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokine (C-X-C motif) receptor 4 (CXCR4) is essential for homing and maintenance of haematopoietic stem cells in distinct stromal cell niches within the marrow. Chemotactic responsiveness of haematopoietic stem cells is restricted to the ligand for CXCR4, stromal cell-derived factor-1 (SDF-1/CXCL12), which is constitutively secreted by marrow stromal cells. Myeloid and lymphoid leukaemia cells also express CXCR4 that induces leukaemia cell chemotaxis and migration beneath marrow stromal cells. CXCR4 expression levels have a major prognostic impact in acute myeloid leukaemia. There is growing in vitro and in vivo evidence that CXCR4 expression by leukaemia cells allows for homing and their retention within the marrow. As such, leukaemia cells appear to utilise CXCR4 to access niches that are normally restricted to progenitor cells, and thereby reside in a microenvironment that favours their growth and survival. CXCR4- and integrin-mediated contact between leukaemia cells and stromal cells protects leukaemia cells from spontaneous and chemotherapy-induced cell death and therefore may represent a mechanism to explain minimal residual disease and subsequent relapses commonly seen in the treatment of these diseases. This review summarises our current knowledge regarding the importance of CXCR4 in acute and chronic leukaemia, discusses the importance of CXCR4 detection by flow cytometry in the diagnostic workup of leukaemia patients, and introduces the potential role of CXCR4-targeting compounds for the treatment of leukaemia patients.

Citing Articles

Diagnostic Approaches in Myeloid Sarcoma.

Patkowska E, Krzywdzinska A, Solarska I, Wojtas M, Prochorec-Sobieszek M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996833 PMC: 11853749. DOI: 10.3390/cimb47020111.


Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies.

Li Y, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z Nat Commun. 2025; 16(1):1248.

PMID: 39893165 PMC: 11787387. DOI: 10.1038/s41467-025-56270-6.


Myeloid Sarcoma: Novel Advances Regarding Molecular Pathogenesis, Presentation and Therapeutic Options.

Diamantidis M J Clin Med. 2024; 13(20).

PMID: 39458104 PMC: 11509401. DOI: 10.3390/jcm13206154.


Potential protective association of the AA genotype and a allele of CXCR4 rs2228014 polymorphism with COVID-19 severity in adult egyptians.

Korayem O, Ahmed A, Meabed M, Magdy D, Abdelghany W BMC Infect Dis. 2024; 24(1):1158.

PMID: 39407172 PMC: 11479566. DOI: 10.1186/s12879-024-09602-8.


The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?.

Abbasifard M, Bagherzadeh K, Khorramdelazad H Front Pharmacol. 2024; 15:1410104.

PMID: 39070795 PMC: 11272485. DOI: 10.3389/fphar.2024.1410104.